April is Parkinson’s Awareness Month, an opportunity to increase public knowledge and understanding of Parkinson’s disease (PD). PD is the second most prevalent neurodegenerative disease and is expected to double by 2040 as the global population ages. Currently, the exact cause of the disease is unknown, and although available therapies treat disease symptoms, they cannot modulate disease progression. Through funding for research and clinical trials, as well as serving as an information resource, the NINDS is working to improve disease burden for individuals living with PD and their families.
The Federal Government is the leading US funder of PD research. In fiscal year 2015, the NINDS funded nearly $97 million out of $146 million in NIH PD research. It continues to support basic, translational and clinical programs aimed at speeding progress towards improved therapies, and an eventual cure, for PD. Through innovative research initiatives including the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research, the Parkinson’s Disease Biomarkers Program (PDBP), and Brain Research though Advancing Innovative Neurotechnologies (BRAIN) Initiative, the NINDS continues to gain new insight into how to slow disease progression, treat, and prevent PD. To learn more about NINDS efforts in PD research contact Dr. Beth-Anne Sieber, NINDS Program Director.
- NINDS News on Twitter
- NINDS Parkinson's Disease 2014 Conference: Advancing Research, Improving Lives: To inform ongoing and future efforts in PD research, the NINDS organized the “PD2014” conference (January 6-7, 2014). At this public meeting, participants assessed significant challenges and identified the highest research priorities for advancing basic, translational and clinical research on PD. The research recommendations and access to the archived meeting webcast are available.
- NINDS PDBP on NINDS YouTube Channel: NINDS Deputy Director Dr. Walter Koroshetz and PDBP investigators Drs. Bowman, Chen-Plotkin, Dewey, Scherzer and Zhang discuss the goals and potential of the program, as well as how the community can become involved.
- NINDS Parkinson’s Disease Biomarkers Program (PDBP): to overcome current roadblocks to better clinical trial design through improved assessment of PD progression across the disease spectrum, the NINDS PDBP will focus on building resources and supporting research that promotes the discovery of diagnostic and progression biomarkers for PD.